Navigation Links
CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies

Researchers from the Spanish National Cancer Research Centre (CNIO), led by Jorge L. Martnez-Torrecuadrada from the Proteomics Unit, have demonstrated that the antibody-based blocking of ephrinB2, a protein involved in angiogenesis and lymphoangiogenesis, may represent an effective strategy for the development of antiangiogenic and antitumoural therapies.

The results of this study appeared in this month's issue of Blood, the journal of the American Society of Hematology.

CNIO researchers generated highly-specific human antibodies against ephrin-B2 using a phage display approach. These specific antibodies were able to suppress endothelial cell migration and tube formation in in vitro assays. Also, systemic treatment of mice xenografted with pancreatic, lung or colon carcinoma cells resulted in a significant reduction in the amount of blood and lymphatic vessels.

Concomitantly, a drastic inhibition of the tumour growth was observed in every xenograft mouse model used. Therefore, these results validated ephrinB2 as a potential therapeutic target in tumour angiogenesis and lymphangiogenesis and showed that the ephrinB2-specific antibodies developed in this study may be suitable as leads for the development of new improved antiangiogenic therapies, which can be used alone or can complement or synergise with other established antiangiogenic therapies of application in cancer or other angiogenesis-related pathologies.

The angiogenesis process

Angiogenesis is a complex process by which new blood vascular vessels arise from pre-existing ones. In adulthood and under physiological conditions, this process only occurs in some circumstances, such as wound healing or in the menstrual cycle, but it is also an important factor in several pathologies such as cancer, in which the tumour promotes the formation of new blood vessels. This new vasculature provides the tumour with oxygen and nutrients, allowing these cells to grow, invade nearby tissue and eventually metastasise to distant organs.

In addition to blood vasculature, tumour growth induces the development of lymphatic vessels in a similar process called lymphangiogenesis that plays a key role in tissuefluid homeostasis, as a tissue-drainage system. Recent studies also demonstrated the critical importance of this lymphatic vasculature for the metastatic spread of tumour cells.

In the last decades, the extensive research in the field of tumour-derived angiogenesis led to the identification of several angiogenic targets that can be effectively blocked in order to prevent the formation of new blood vessels in tumours, starving them of oxygen and nutrients and thereby preventing their growth.

As a result of these researches, several antibodies have been successfully developed and have demonstrated clinical utility in treating several tumour types, such as bevacizumab (Avastin), which is based on the inhibition of vascular endothelial growth factor (VEGF) that promotes endothelial cell proliferation, migration and differentiation.

However, recent emerging experimental and clinical evidence suggests that tumours treated with this antiangiogenic strategy may eventually develop resistance to therapy and exhibit a progression to greater invasiveness. Therefore, there is a pressing need to explore other angiogenic targets that can be used therapeutically, such as the one validated by CNIO researchers in the study now published in Blood.


Contact: Juan J. Gomez
Centro Nacional de Investigaciones Oncologicas (CNIO)

Related biology technology :

1. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
2. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
3. Multidisciplinary team of researchers develop world’s lightest material
4. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
5. Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow
6. UCLA researchers demonstrate fully printed carbon nanotube transistor circuits for displays
7. Penn and Brown researchers demonstrate earthquake friction effect at the nanoscale
8. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
9. Researchers develop one of the worlds smallest electronic circuits
10. MU researchers identify key plant immune response in fight against bacteria
11. Researchers realize high-power, narrowband terahertz source at room temperature
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
Breaking Biology Technology:
(Date:8/15/2017)... Va. , Aug. 15 2017   ivWatch LLC , ... of intravenous (IV) therapy, today announced receipt of its ISO 13485 ... developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the ... "This is ...
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
Breaking Biology News(10 mins):